Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at [email protected] in case you face any issues.

loading page

Autoreactive IgE: pathogenic role and therapeutic target in autoimmune diseases
  • +7
  • Nicolas CHARLES,
  • Inge Kortekaas Krohn,
  • Emek Kocatürk,
  • Jörg Scheffel,
  • Sabine Altrichter,
  • Carolin Steinert,
  • Yi-Kui Xiang,
  • Jan Gutermuth,
  • Laurent Reber,
  • Marcus Maurer
Nicolas CHARLES
INSERM

Corresponding Author:[email protected]

Author Profile
Inge Kortekaas Krohn
Vrije Universiteit Brussel - Brussels Health Campus
Author Profile
Emek Kocatürk
Koç University School of Medicine
Author Profile
Jörg Scheffel
Charite Universitatsmedizin Berlin
Author Profile
Sabine Altrichter
Charite Universitatsmedizin Berlin
Author Profile
Carolin Steinert
Charite Universitatsmedizin Berlin
Author Profile
Yi-Kui Xiang
Charite Universitatsmedizin Berlin
Author Profile
Jan Gutermuth
Vrije Universiteit Brussel - Brussels Health Campus
Author Profile
Laurent Reber
Toulouse Institute for Infectious and Inflammatory Diseases (Infinity
Author Profile
Marcus Maurer
Charite Universitatsmedizin Berlin
Author Profile

Abstract

Autoimmunity is the break of tolerance to self-antigens that leads to organ-specific or systemic diseases characterized by the presence of pathogenic autoreactive antibodies (AAb) produced by plasmablast and/or plasma cells. AAb are prevalent in the general population and not systematically associated with clinical symptoms. In contrast, in some individuals, these AAb are pathogenic and drive the development of signs and symptoms of antibody-mediated autoimmune diseases (AbAID). AAb production, isotype profiles, and glycosylations are promoted by pro-inflammatory triggers linked to genetic, environmental, and hormonal parameters. Recent evidence supports a role for pathogenic AAb of the IgE isotype in a number of AbAID. Autoreactive IgE can drive the activation of mast cells, basophils and other types of FcεRI-bearing cells and may play a role in promoting autoantibody production and other pro-inflammatory pathways. In this review, we discuss the current knowledge on the pathogenicity of autoreactive IgE in AbAID and their status as therapeutic targets. We also highlight unresolved issues including the need for assays that reproducibly quantify IgE AAbs, to validate their diagnostic and prognostic value, and to further study their pathophysiological contributions to AbAID.
19 Apr 2023Submitted to Allergy
19 Apr 2023Submission Checks Completed
19 Apr 2023Assigned to Editor
19 Apr 2023Review(s) Completed, Editorial Evaluation Pending
28 Apr 2023Reviewer(s) Assigned
23 May 2023Editorial Decision: Revise Minor
08 Jun 20231st Revision Received
08 Jun 2023Submission Checks Completed
08 Jun 2023Assigned to Editor
08 Jun 2023Review(s) Completed, Editorial Evaluation Pending
19 Jun 2023Reviewer(s) Assigned
05 Jul 2023Editorial Decision: Revise Minor
09 Jul 20232nd Revision Received
10 Jul 2023Submission Checks Completed
10 Jul 2023Assigned to Editor
10 Jul 2023Review(s) Completed, Editorial Evaluation Pending
27 Jul 2023Editorial Decision: Accept